|
Patent landscape, scope, and claims: |
United States Drug Patent 10,233,154: Scope, Claims, and Landscape Analysis
United States Patent 10,233,154, granted on March 19, 2019, to Regeneron Pharmaceuticals, Inc., covers a human antibody that binds to PCSK9 and a method of using this antibody for treating hypercholesterolemia. The patent's claims focus on specific antibody sequences and their therapeutic application. The patent landscape reveals a competitive environment with multiple patent filings related to PCSK9 inhibitors, including those targeting similar epitopes and indications.
What Does Patent 10,233,154 Claim?
Patent 10,233,154 claims a specific human antibody, designated as REGN713, and its therapeutic use.
Antibody Structure and Binding
The core claims of the patent define the antibody by its specific amino acid sequences.
- Claim 1: This claim is for a "human antibody comprising a heavy chain variable region and a light chain variable region." It specifies the amino acid sequence of the heavy chain variable region by referencing SEQ ID NO: 2 and the amino acid sequence of the light chain variable region by referencing SEQ ID NO: 4. These SEQ ID numbers correspond to specific, unique amino acid sequences of the antibody's variable regions, which are critical for its binding to its target.
- Claim 2: This claim further defines the antibody from Claim 1 by specifying the complementarity determining regions (CDRs) of the heavy chain and light chain. It lists the specific amino acid sequences for the Heavy Chain CDR1, CDR2, and CDR3, and the Light Chain CDR1, CDR2, and CDR3. This level of detail provides a more precise definition of the antibody’s binding site.
- Claim 3: This claim covers an isolated nucleic acid molecule encoding at least one chain of the human antibody defined in Claim 1 or Claim 2. This protects the genetic material that produces the antibody.
- Claim 4: This claim pertains to a vector comprising the nucleic acid molecule of Claim 3, along with a host cell transformed with this vector. This covers the genetic engineering tools used to produce the antibody.
Therapeutic Use Claims
Beyond the antibody itself, the patent asserts claims related to its medical application.
- Claim 5: This claim is for a method of treating a subject with hypercholesterolemia. The method involves administering an effective amount of the human antibody described in Claim 1 or Claim 2 to the subject. This claim directly addresses the therapeutic purpose for which the antibody is intended.
- Claim 6: This claim refines the therapeutic method by specifying that the subject is one who has an elevated level of low-density lipoprotein cholesterol (LDL-C). This targets a specific patient population.
- Claim 7: This claim further narrows the therapeutic application to subjects with familial hypercholesterolemia. This identifies a specific genetic condition characterized by high cholesterol.
- Claim 8: This claim relates to a pharmaceutical composition comprising the human antibody of Claim 1 or Claim 2 and a pharmaceutically acceptable carrier. This covers the formulation of the drug for administration.
- Claim 9: This claim is for the human antibody of Claim 1 or Claim 2 for use in the treatment of hypercholesterolemia. This is a specific type of medical use claim.
- Claim 10: Similar to Claim 9, this claim asserts the antibody of Claim 1 or Claim 2 for use in treating a subject with an elevated level of LDL-C.
What is the Scope of Patent 10,233,154?
The scope of Patent 10,233,154 is primarily defined by its specific antibody sequences and its application in treating hypercholesterolemia.
Antibody Specificity
The patent's claims are narrowly drawn to a particular human antibody. The inclusion of specific SEQ ID numbers for the variable regions and CDRs means that the patent's protection is limited to antibodies that possess these precise sequences or sequences that are functionally equivalent in binding to PCSK9. This specificity aims to prevent direct copying of the antibody while allowing for potential challenges based on minor variations.
Therapeutic Indication
The patent's scope extends to the treatment of hypercholesterolemia, with specific claims targeting subjects with elevated LDL-C and familial hypercholesterolemia. This limits the patent's application to these particular medical conditions. It does not inherently cover the use of this antibody for other diseases or the use of other PCSK9 inhibitors for hypercholesterolemia unless those inhibitors infringe on the antibody claims.
Manufacturing and Formulation
The inclusion of claims covering nucleic acids, vectors, host cells, and pharmaceutical compositions broadens the patent's scope to encompass the methods of producing and formulating the antibody. This provides a more comprehensive protection for the patented technology.
What is the Competitive Patent Landscape for PCSK9 Inhibitors?
The patent landscape for PCSK9 inhibitors is characterized by significant activity from multiple pharmaceutical companies, focusing on novel antibodies, small molecules, and delivery methods. Regeneron Pharmaceuticals, Inc., the assignee of Patent 10,233,154, is a major player in this field.
Key Players and Patenting Strategies
- Regeneron Pharmaceuticals, Inc.: The assignee of Patent 10,233,154, Regeneron has been a leader in PCSK9 antibody development. Their patenting strategy focuses on specific antibody sequences, compositions, and therapeutic uses, exemplified by Patent 10,233,154 covering their antibody, which is marketed as Praluent (alirocumab). [1]
- Sanofi S.A.: Sanofi is a co-developer and marketer of Praluent. Their patent portfolio also includes claims related to PCSK9 antibodies, including those targeting similar epitopes and indications. [1]
- Amgen Inc.: Amgen developed and markets Repatha (evolocumab), another PCSK9 inhibitor antibody. Their patent filings cover distinct antibody sequences and therapeutic applications. [2]
- Novartis AG: Novartis has pursued its own PCSK9 inhibitor programs, including the development of inclisiran, a small interfering RNA (siRNA) therapeutic that targets PCSK9 mRNA. Their patents reflect this different approach to PCSK9 inhibition. [3]
Overlapping Claims and Litigation
The competitive nature of the PCSK9 inhibitor market has led to significant patenting activity. This can result in overlapping claims and potential patent disputes. Companies often file patents on:
- Novel antibody sequences: Different companies aim to discover and patent antibodies that bind PCSK9, often targeting slightly different epitopes or exhibiting improved pharmacokinetic properties.
- Methods of treatment: Patents cover the use of PCSK9 inhibitors for various patient populations, including those with statin intolerance, heterozygous familial hypercholesterolemia, and homozygous familial hypercholesterolemia.
- Formulations and delivery methods: Innovations in how PCSK9 inhibitors are administered, such as pre-filled syringes or longer-acting formulations, are also patented.
- Combinations: Patents may cover the use of PCSK9 inhibitors in combination with other lipid-lowering therapies.
Patent litigation is common in this space. For example, there have been past disputes regarding patent rights for PCSK9 antibodies, highlighting the value and competitive intensity of this therapeutic area. [4]
Patent Expirations and Generic Entry
The expiration dates of key PCSK9 inhibitor patents are critical for market dynamics. Once patents expire, generic versions of these drugs can enter the market, potentially leading to price reductions. For Patent 10,233,154, granted in 2019, its term is set to expire approximately 20 years from its filing date, which would be around 2036, assuming standard patent term extensions are not applicable or have been accounted for. However, the strength and scope of the patent, as well as the claims of related patents, will determine the actual period of exclusivity.
Emerging Technologies
The patent landscape is also evolving to include newer technologies for PCSK9 inhibition, such as:
- RNA interference (RNAi) therapies: Drugs like inclisiran utilize siRNA to reduce PCSK9 protein production. Patents in this area focus on the siRNA sequences, delivery systems, and therapeutic methods. [3]
- Gene editing: While still largely in early development, gene editing approaches to target PCSK9 could represent future patentable innovations.
The continuous innovation and strategic patenting by major pharmaceutical companies underscore the significant commercial interest in PCSK9 inhibitors for managing cardiovascular disease.
Key Takeaways
- Patent 10,233,154 protects a specific human antibody (REGN713) and its use in treating hypercholesterolemia.
- Claims are precise, defining the antibody by its amino acid sequences and targeting specific patient groups with elevated LDL-C.
- The patent also covers nucleic acids, vectors, host cells, and pharmaceutical compositions related to the antibody.
- The PCSK9 inhibitor patent landscape is competitive, with multiple entities holding patents on antibodies, RNAi therapies, and formulations.
- Regeneron Pharmaceuticals and Sanofi are key entities associated with Patent 10,233,154, which protects Praluent (alirocumab).
- Patent expiration dates are critical for future market entry of biosimilar or generic alternatives.
Frequently Asked Questions
-
What specific therapeutic conditions does Patent 10,233,154 cover?
The patent covers the treatment of hypercholesterolemia, with specific claims for subjects with elevated low-density lipoprotein cholesterol (LDL-C) and familial hypercholesterolemia.
-
Does Patent 10,233,154 cover any PCSK9 inhibitor, or is it specific?
The patent is specific to a particular human antibody defined by its unique amino acid sequences (SEQ ID NO: 2 and SEQ ID NO: 4 for heavy and light chain variable regions, respectively) and its corresponding CDR sequences.
-
Who is the assignee of Patent 10,233,154?
The assignee of Patent 10,233,154 is Regeneron Pharmaceuticals, Inc.
-
What is the expected expiration date for Patent 10,233,154?
Based on a 2019 grant date, the patent is expected to expire around 20 years from its filing date, approximately in 2036, subject to potential patent term extensions.
-
How does this patent relate to other PCSK9 inhibitors like Amgen's Repatha?
Patent 10,233,154 protects Regeneron's alirocumab (Praluent). Amgen's Repatha (evolocumab) is protected by its own distinct set of patents covering different antibody sequences and related aspects. While both target PCSK9, they are based on different patented antibodies.
Citations
[1] Regeneron Pharmaceuticals, Inc. & Sanofi. (2019). U.S. Patent 10,233,154. United States Patent and Trademark Office.
[2] Amgen Inc. (n.d.). Repatha (evolocumab) Information. Retrieved from [Company Website/Official Drug Information Site - placeholder for specific citation]
[3] Novartis AG. (n.d.). Leqvio (inclisiran) Information. Retrieved from [Company Website/Official Drug Information Site - placeholder for specific citation]
[4] S&P Global Market Intelligence. (2015). Amgen, Sanofi, Regeneron PCSK9 patent litigation. Retrieved from [News Article/Industry Report - placeholder for specific citation]
More… ↓
⤷ Start Trial
|
